MiniMed Group, Inc. Common Stock
NASDAQ:MMEDMedical - Care Facilities
+$0.40 today
- Market cap
- $4.78B
- Beta
- -3.63
- P/E (TTM)
- -14.2
- EPS (TTM)
- -$1.91
Volume 4.70M
Average 0.95M
MMED Sales of Investments
Cash received from selling or redeeming investments.
MiniMed Group, Inc. Common StockNASDAQ: MMED
Sales of Investments · Q1 FY2026 · quarter ended Jul 2026
Sales of investments of $0 in Q1 FY2026
Q1 FY2026 sales of investments was $0. Trailing-twelve-month sales of investments was $0.
Context
- Sales of investments amounted to 0.0% of revenue in FY2025, unchanged from a year earlier.
- Sales of investments increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly sales of investments holds near $0 or moves back toward the trailing-twelve-month quarterly average of $0.
Sources:Cash FlowText generated from reported figures; not investment advice.
Sales of Investments history
USD · from the cash flow
- Latest · FY2025
- 0 USD
- Year-over-year change
- —
| Period | Period end | Sales of Investments | YoY change |
|---|---|---|---|
| FY2025 | 2026-04-24 | 0 | — |
| FY2024 | 2025-04-30 | 0 | -100.0% |
| FY2023 | 2024-04-30 | 11M | — |
| FY2022 | 2023-04-30 | 0 | — |
Sales of Investments vs competitors
How MMED compares with its peers on the latest reported figures
- MMED's LTM Jul 2026 sales of investments of $0 is the 6th largest of the 7 companies compared; the peer median is $176.23M.
- Sales of investments amounts to 0.0% of revenue for MMED, versus a peer median of 29.9%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jul 2026 | $8.3B | -0.5% | +3.3% | 22.1% | |
| LTM Jun 2026 | $1.87B | -19.6% | +0.6% | 37.6% | |
| LTM Mar 2026 | $190M | +106.5% | — | 172.4% | |
| LTM Mar 2026 | $162.47M | -43.6% | -23.3% | 15.8% | |
| LTM Mar 2026 | $71.65M | +6.3% | -28.4% | 176.0% | |
MMEDMiniMed Group, Inc. Common Stock | LTM Jul 2026 | $0 | — | — | 0.0% |
| LTM Jun 2026 | $0 | — | — | 0.0% | |
MMEDVMiniMed Group, Inc. | — | — | — | — | — |
| Peer median (excluding MMED) | $176.23M | -0.5% | -11.4% | 29.9% | |
Competitors are the stored peer set for MMED. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2022 Apr 2023 | FY2023 Apr 2024 | FY2024 Apr 2025 | FY2025 Apr 2026 |
|---|---|---|---|---|
| Net Income | (92M) | (107M) | (198M) | (317M) |
| Depreciation & Amortization | 115M | 129M | 143M | 156M |
| Deferred Income Tax | (11M) | 3M | (2M) | (54M) |
| Stock-Based Compensation | 35M | 38M | 41M | 46M |
| Change in Working Capital | (90M) | (74M) | 122M | (166M) |
| Accounts Receivables | (70M) | (105M) | (66M) | (538M) |
| Inventory | (28M) | 5M | (19M) | (29M) |
| Accounts Payables | 14M | (4M) | 191M | 41M |
| Other Working Capital | (6M) | 30M | 16M | 360M |
| Other Non-Cash Items | 37M | 52M | 34M | 138M |
| Operating Cash Flow | (6M) | 41M | 140M | (197M) |
| Capital Expenditures | (167M) | (148M) | (193M) | (223M) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 |
| Purchases of Investments | (13M) | (5M) | 0 | 0 |
| Sales of Investments | 0 | 11M | 0 | 0 |
| Other Investing Activities | 0 | (15M) | 0 | (10M) |
| Investing Cash Flow | (180M) | (157M) | (193M) | (233M) |
| Debt Repayment | 0 | 0 | 0 | 0 |
| Common Stock Issued | 0 | 0 | 0 | 538M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 |
| Other Financing Activities | 185M | 112M | 10M | 178M |
| Financing Cash Flow | 185M | 112M | 10M | 716M |
| Effect of Forex Changes | 0 | 0 | 0 | 1M |
| Net Change in Cash | (2M) | (4M) | (43M) | 287M |
| Free Cash Flow | (173M) | (107M) | (53M) | (420M) |
MiniMed Group, Inc. Common Stock
NASDAQ:MMED
Intrinsic Alpha fair value
Locked
Current Price
$16.99
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.